These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20358441)

  • 21. QT analysis: a complex answer to a 'simple' problem.
    Li L; Desai M; Desta Z; Flockhart D
    Stat Med; 2004 Sep; 23(17):2625-43. PubMed ID: 15316947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A note on one-sided tests with multiple endpoints.
    Perlman MD; Wu L
    Biometrics; 2004 Mar; 60(1):276-9; discussion 279-80. PubMed ID: 15032799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to letter to the editor: Statistical issues of QT prolongation assessment based on linear concentration modeling by Yi Tsong et al.
    Wang Y; Garnett C
    J Biopharm Stat; 2010 May; 20(3):689-92; author reply 693-7. PubMed ID: 20358447
    [No Abstract]   [Full Text] [Related]  

  • 24. An efficient and robust analysis of covariance model for baseline adjustment in parallel-group thorough QT/QTc studies.
    Lu K
    Stat Med; 2013 Jun; 32(14):2406-18. PubMed ID: 22996035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The joint modeling of drug and positive control effects to estimate sample size and power in crossover "thorough" QT/QTc studies.
    Hosmane B; Locke C; Chiu YL
    J Biopharm Stat; 2013; 23(4):871-80. PubMed ID: 23786591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of gatekeeping and other testing methods for identifying superior drug combinations in bifactorial designs with isotonic parameters.
    Soulakova JN
    J Biopharm Stat; 2011 Jul; 21(4):635-49. PubMed ID: 21516561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Model averaging for robust assessment of QT prolongation by concentration-response analysis.
    Dosne AG; Bergstrand M; Karlsson MO; Renard D; Heimann G
    Stat Med; 2017 Oct; 36(24):3844-3857. PubMed ID: 28703360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superiority inferences on individual endpoints following noninferiority testing in clinical trials.
    Logan BR; Tamhane AC
    Biom J; 2008 Oct; 50(5):693-703. PubMed ID: 18932132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sevoflurane causes greater QTc interval prolongation in elderly patients than in younger patients.
    Nakao S; Hatano K; Sumi C; Masuzawa M; Sakamoto S; Ikeda S; Shingu K
    Anesth Analg; 2010 Mar; 110(3):775-9. PubMed ID: 20185656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical analysis of joint short-term and long-term survival in resuscitation research.
    Babbs CF
    Resuscitation; 2007 Nov; 75(2):323-31. PubMed ID: 17583410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multistage and mixture parallel gatekeeping procedures in clinical trials.
    Dmitrienko A; Kordzakhia G; Tamhane AC
    J Biopharm Stat; 2011 Jul; 21(4):726-47. PubMed ID: 21516566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the assessment of dose proportionality: a comparison of two slope approaches.
    Cheng B; Chow SC; Su WL
    J Biopharm Stat; 2006 May; 16(3):385-92. PubMed ID: 16724492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three methods for constructing parallel gatekeeping procedures in clinical trials.
    Dmitrienko A; Soulakova JN; Millen BA
    J Biopharm Stat; 2011 Jul; 21(4):768-86. PubMed ID: 21516568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time domain parameters can be estimated with less statistical error than frequency domain parameters in the analysis of heart rate variability.
    Kuss O; Schumann B; Kluttig A; Greiser KH; Haerting J
    J Electrocardiol; 2008; 41(4):287-91. PubMed ID: 18367200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marginal modeling of binary cross-over data.
    Becker MP; Balagtas CC
    Biometrics; 1993 Dec; 49(4):997-1009. PubMed ID: 8117910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.
    Rohatagi S; Carrothers TJ; Kuwabara-Wagg J; Khariton T
    J Clin Pharmacol; 2009 Nov; 49(11):1284-96. PubMed ID: 19734373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On analyzing circadian rhythms data using nonlinear mixed models with harmonic terms.
    Albert PS; Hunsberger S
    Biometrics; 2005 Dec; 61(4):1115-20; discussion 1120-2. PubMed ID: 16401286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A flexible strategy for testing subgroups and overall population.
    Alosh M; Huque MF
    Stat Med; 2009 Jan; 28(1):3-23. PubMed ID: 18985704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.
    Anderson JJ; Bolognese JA; Felson DT
    Arthritis Rheum; 2003 Nov; 48(11):3031-8. PubMed ID: 14613263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.